Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
NCT04348916 is registered in ClinicalTrials.gov with Oncorus, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
- Lead sponsor
- Oncorus, Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- May 20, 2020
- Completion date
- May 31, 2023
- Enrollment
- 66 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumor, breast cancer, cancer, colorectal carcinoma, liver metastases, melanoma, non-melanoma skin cancer, solid tumor, squamous cell carcinoma of head and neck, triple negative breast cancer